X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1928) 1928
peginterferon alpha-2a (1813) 1813
antiviral agents - therapeutic use (1241) 1241
gastroenterology & hepatology (1219) 1219
hepatitis c, chronic - drug therapy (994) 994
male (960) 960
female (932) 932
hepatitis c (903) 903
ribavirin (835) 835
middle aged (825) 825
interferon-alpha - therapeutic use (818) 818
adult (797) 797
treatment outcome (776) 776
interferon (739) 739
drug therapy, combination (698) 698
ribavirin - therapeutic use (684) 684
genotype (614) 614
hepacivirus - genetics (605) 605
plus ribavirin (604) 604
polyethylene glycols - therapeutic use (602) 602
recombinant proteins (592) 592
hepatitis c virus (535) 535
therapy (512) 512
combination therapy (464) 464
antiviral agents - administration & dosage (451) 451
infectious diseases (439) 439
virus-infection (428) 428
hepatitis (403) 403
virology (399) 399
sustained virological response (389) 389
pharmacology & pharmacy (377) 377
hepatitis c, chronic - virology (372) 372
viral load (368) 368
interferon-alpha - administration & dosage (366) 366
hepatitis c - drug therapy (361) 361
initial treatment (360) 360
infection (351) 351
combination (350) 350
hepacivirus - drug effects (348) 348
antiviral agents - adverse effects (337) 337
health aspects (337) 337
biological response modifiers (333) 333
ribavirin - administration & dosage (333) 333
pegylated interferon (329) 329
aged (327) 327
care and treatment (315) 315
chronic hepatitis-c (295) 295
hepatitis b, chronic - drug therapy (295) 295
hepatocellular-carcinoma (295) 295
peginterferon (294) 294
drug therapy (288) 288
hepatitis b (285) 285
polyethylene glycols - administration & dosage (282) 282
recombinant proteins - therapeutic use (267) 267
antiviral therapy (252) 252
interferon-alpha-2b plus ribavirin (252) 252
rna, viral - blood (251) 251
virus diseases (250) 250
lamivudine (247) 247
antiviral agents (246) 246
interferon-alpha - adverse effects (245) 245
virus (238) 238
chronic hepatitis c (231) 231
medicine, general & internal (230) 230
natural-history (228) 228
hcv (221) 221
pegylated interferon-alpha-2b (217) 217
virological response (217) 217
gastroenterology and hepatology (214) 214
cirrhosis (212) 212
ribavirin - adverse effects (210) 210
randomized-trial (202) 202
telaprevir (200) 200
time factors (200) 200
hepatitis c, chronic - complications (194) 194
interferon-alpha (187) 187
management (186) 186
retrospective studies (186) 186
alpha-2a plus ribavirin (184) 184
analysis (184) 184
efficacy (179) 179
peginterferon alpha-2b (175) 175
polyethylene glycols - adverse effects (173) 173
sustained response (170) 170
infections (168) 168
interferons - therapeutic use (168) 168
digestive system diseases (166) 166
risk factors (165) 165
genetic aspects (164) 164
research (164) 164
chronic hepatitis b (161) 161
immunology (161) 161
adefovir dipivoxil (160) 160
antiviral agents - pharmacology (160) 160
alpha-2b plus ribavirin (159) 159
hepatology (158) 158
hepacivirus - isolation & purification (157) 157
liver (157) 157
rna (156) 156
treatment-naive patients (153) 153
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2456) 2456
French (35) 35
Spanish (32) 32
German (22) 22
Korean (9) 9
Portuguese (4) 4
Serbian (3) 3
Hungarian (2) 2
Japanese (2) 2
Chinese (1) 1
Polish (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Ophthalmology, ISSN 1471-2415, 02/2018, Volume 18, Issue 1, pp. 52 - 4
Background: To evaluate therapeutic outcomes of interferon alpha-2a (IFN alpha 2a) treatment in patients with Behcet's disease who were refractory to immunosuppressive agents... 
Behcet syndrome | Interferon-alpha | Therapeutics | Uveitis | TRIAL | THERAPY | SAFETY | DISEASE | OPHTHALMOLOGY | LONG-TERM EFFICACY | Peginterferon alfa-2a | Behcet's disease | Dosage and administration | Research | Drug therapy | Biological response modifiers | Immunosuppressive agents
Journal Article
中华医学杂志:英文版, ISSN 0366-6999, 2017, Volume 130, Issue 5, pp. 559 - 565
Journal Article
世界胃肠病学杂志:英文版(电子版), ISSN 1007-9327, 2014, Volume 20, Issue 16, pp. 4681 - 4691
AIM:To investigate the safety and efficacy of a Hansenula-derived PEGylated(polyethylene glycol)interferon(IFN)-alpha-2a(Reiferon Retard)plus ribavirin customized regimen in treatment-na... 
Chronic | C | Children | hepatitis | Hansenula | polymorpha | Chronic hepatitis C | Treatment | Pegylated interferon | Response rate | Hansenula polymorpha | Ribavirin | DIAGNOSIS | PLUS RIBAVIRIN | VIRUS-INFECTION | MANAGEMENT | VIROLOGICAL RESPONSE | PEGylated interferon | THERAPY | PEGINTERFERON ALPHA-2B | ADOLESCENTS | GENOTYPE 4 | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Recurrence | Age Factors | Humans | Egypt | Child, Preschool | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | RNA, Viral - blood | Recombinant Proteins - adverse effects | Recombinant Proteins - biosynthesis | Polyethylene Glycols - therapeutic use | Viral Load | Young Adult | Pichia - metabolism | Interferon-alpha - genetics | Time Factors | Injections, Subcutaneous | Ribavirin - administration & dosage | Female | Drug Therapy, Combination | Child | Biomarkers - metabolism | Hepacivirus - drug effects | Tertiary Care Centers | Drug Administration Schedule | Administration, Oral | Antiviral Agents - therapeutic use | Interferon-alpha - biosynthesis | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Treatment Outcome | Recombinant Proteins - genetics | Hepatitis C, Chronic - diagnosis | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Remission Induction | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Pichia - genetics | Hepacivirus - growth & development | Interferon-alpha - adverse effects | Brief
Journal Article
Journal Article
International journal of nanomedicine, ISSN 1178-2013, 2007, Volume 2, Issue 1, pp. 19 - 24
... of chronic hepatitis C – focus on pegylated interferon alpha-2a Thea Thomas1 Graham Foster2 1Specialist Registrar in Gastroenterology, University College London Hospital... 
pegylation | PEGINTERFERON ALPHA-2A | EFFICACY | SAFETY | nanomedicines | hepatitis C | ALPHA-2A PEGASYS(TM) | nanotechnology | NANOSCIENCE & NANOTECHNOLOGY | PHARMACOLOGY & PHARMACY | pegylated interferon | 40 kDa pegylated interferon alpha-2a | Interferon | Nanotechnology
Journal Article
Hepatitis Monthly, ISSN 1735-143X, 09/2015, Volume 15, Issue 9, p. e30780
Background: Nearly 0.5% of Iranians are infected with HCV. Peginterferon-alpha-2a and Peginterferon-alpha-2b are the two available types of interferon for the treatment of hepatitis C... 
Peginterferon alfa-2b | Peginterferon alfa-2a | Iran | Hepatitis C | PLUS RIBAVIRIN | THERAPY | METAANALYSIS | SAFETY | PEGYLATED INTERFERON | INFECTION | HCV | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Hepatitis research and treatment, ISSN 2090-1364, 4/2017, Volume 2017, pp. 2093847 - 7
...1. Introduction The current standard treatment for patients with chronic hepatitis B (HB) is pegylated interferon alpha-2a (PEG-IFN-α-2a) or nucleoside analogs... 
Control | Dosage and administration | Peginterferon alfa-2a | Drug therapy | Entecavir | Hepatitis B | Clinical Study
Journal Article
Hepatitis Monthly, ISSN 1735-143X, 05/2013, Volume 13, Issue 5, p. e10069
...: assessing the effects of Peginterferon alpha-2a versus Peginterferon alpha-2b on the sustained virological response in naive chronic HCV genotype-4 Egyptian patients... 
Peginterferon-alpha-2a | Chronic hepatitis C | Peginterferon-alpha-2b | TRIAL | PEGYLATED INTERFERON ALPHA-2A | PLUS RIBAVIRIN | VIRUS-INFECTION | THERAPY | EFFICACY | Chronic Hepatitis C | CHRONIC HEPATITIS-C | Peginterferon-Alpha-2a | GASTROENTEROLOGY & HEPATOLOGY | Peginterferon-Alpha-2b
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2012, Volume 7, Issue 11, p. e48959
Background: The aim of the study was to analyze the different impact of standard and low-dose Peg-IFN-alpha 2a/RBV therapies on HCV viral decline in HIV/HCV... 
VIRUS | THERAPY | PEGINTERFERON ALPHA-2A | HIV | KINETICS | MULTIDISCIPLINARY SCIENCES | CHRONIC HEPATITIS-C | PEGYLATED INTERFERON | ALPHA-2A PLUS RIBAVIRIN | COMBINATION | PREDICTION | Prospective Studies | Hepatitis C - drug therapy | Coinfection - drug therapy | Humans | Hepacivirus - genetics | Male | Dose-Response Relationship, Drug | Hepatitis C - blood | Ribavirin - administration & dosage | Adult | Female | HIV Infections - blood | Antiviral Agents - therapeutic use | HIV Infections - genetics | HIV Infections - virology | Genotype | Hepatitis C - genetics | Treatment Outcome | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | HIV - growth & development | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Coinfection - genetics | Hepatitis C - virology | HIV - genetics | HIV Infections - drug therapy | Hepacivirus - growth & development | Viral Load - drug effects | Infection | Care and treatment | Analysis | HIV patients | Genetic aspects | Interferon | Biological response modifiers | Hepatitis C virus | Health aspects | Standards | Ribavirin | Biomedical research | Liver | Regression analysis | Dosage | Patients | Impact analysis | Hepatitis | α-Interferon | Regression models | Infectious diseases | Polyethylene glycol | Biopsy | Hepatology | Human immunodeficiency virus--HIV | Drug dosages | Human immunodeficiency virus
Journal Article